Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
OncoMed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
OncoMed Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
OncoMed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
OncoMed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
OncoMed Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10
OncoMed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
OncoMed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
OncoMed Pharma Partners with Guardant Health 12
OncoMed Pharma Enters Into Co-Development Agreement With Celgene 13
Genomic Health Enters Into Co-Development Agreement With OncoMed Pharma 15
Molecular Response Enters Into Co-Development Agreement With OncoMed Pharma 16
Licensing Agreements 17
Lonza Enters Into Licensing Agreement With OncoMed Pharma For GS Gene Expression System 17
Equity Offering 18
OncoMed Pharma Plans to Raise USD150 Million in Public Offering of Securities 18
OncoMed Pharma Raises USD4.9 Million in Public offering of Shares 19
OncoMed Pharma Raises USD63.3 Million in Public Offering of Shares 20
OncoMed Pharma Completes IPO Of Shares For US$93.8 Million 22
OncoMed Pharmaceuticals Inc – Key Competitors 24
OncoMed Pharmaceuticals Inc – Key Employees 25
OncoMed Pharmaceuticals Inc – Locations And Subsidiaries 26
Head Office 26
Recent Developments 27
Financial Announcements 27
Aug 02, 2018: OncoMed announces second quarter 2018 financial results and operational highlights 27
May 08, 2018: OncoMed Announces First Quarter 2018 Financial Results and Operational Highlights 29
Mar 08, 2018: OncoMed Announces Fourth Quarter and Full Year 2017 Financial Results and Operational Highlights 31
Nov 02, 2017: OncoMed Announces Third Quarter 2017 Financial Results and Operational Highlights 33
Aug 02, 2017: OncoMed Announces Second Quarter 2017 Financial Results 35
May 08, 2017: OncoMed Announces First Quarter 2017 Financial Results and Demcizumab DENALI Results 36
Corporate Communications 38
Mar 19, 2018: OncoMed Names John Lewicki As President, CEO And Board Member 38
Jan 04, 2018: OncoMed Announces Chairman, President and Chief Executive Officer Paul J. Hastings has Resigned 39
Nov 27, 2017: OncoMed Announces Chairman, President and Chief Executive Officer Paul J. Hastings to Resume Chairman Responsibilities 40
Apr 24, 2017: OncoMed Announces Workforce Reduction 41
Clinical Trials 42
Jun 12, 2018: OncoMed Doses First Patient in Phase 1b Portion of anti-TIGIT Clinical Trial 42
Apr 18, 2018: OncoMed Presents Preclinical Abstract On anti-TIGIT (OMP-313M32) At The 2018 American Association for Cancer Research Annual Meeting 43
Apr 09, 2018: OncoMed to Present Preclinical Data for OMP-313M32 at the 2018 American Association for Cancer Research Annual Meeting 44
Sep 13, 2017: OncoMed Doses First Patient with GITRL-Fc in Phase 1a Clinical Trial 45
May 04, 2017: OncoMed Doses First Patient with Anti-TIGIT Antibody in Phase 1 Clinical Trial 46
Apr 05, 2017: OncoMed Announces Presentation on Rosmantuzumab at the American Association for Cancer Research Annual Meeting 2017 47
Apr 05, 2017: OncoMed Highlights Data Presented on GITRL-Fc trimer at the American Association for Cancer Research Annual Meeting 2017 48
Apr 03, 2017: OncoMed Presents Preclinical Data for Anti-TIGIT Program at the American Association for Cancer Research Annual Meeting 2017 49
Feb 13, 2017: OncoMed Enrolls First Patient in Phase 1b Clinical Trial of its Anti-DLL4/VEGF Bispecific Antibody in Patients with Platinum-Resistant Ovarian Cancer 51
Jan 04, 2017: OncoMed Initiates Enrollment of Phase 1b Clinical Trial of Anti-DLL4/VEGF Bispecific Antibody as Second-line Treatment for Metastatic Colorectal Cancer Patients 52
Other Significant Developments 53
Jan 04, 2018: OncoMed Provides 2018 Outlook and 2017 Year-End Cash Balance and Announces an Update on the Rosmantuzumab Program 53
Jan 05, 2017: OncoMed Announces Year-End Cash Balance and 2017 Outlook 54
Appendix 56
Methodology 56
About GlobalData 56
Contact Us 56
Disclaimer 56
OncoMed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
OncoMed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
OncoMed Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
OncoMed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
OncoMed Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
OncoMed Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10
OncoMed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
OncoMed Pharma Partners with Guardant Health 12
OncoMed Pharma Enters Into Co-Development Agreement With Celgene 13
Genomic Health Enters Into Co-Development Agreement With OncoMed Pharma 15
Molecular Response Enters Into Co-Development Agreement With OncoMed Pharma 16
Lonza Enters Into Licensing Agreement With OncoMed Pharma For GS Gene Expression System 17
OncoMed Pharma Plans to Raise USD150 Million in Public Offering of Securities 18
OncoMed Pharma Raises USD4.9 Million in Public offering of Shares 19
OncoMed Pharma Raises USD63.3 Million in Public Offering of Shares 20
OncoMed Pharma Completes IPO Of Shares For US$93.8 Million 22
OncoMed Pharmaceuticals Inc, Key Competitors 24
OncoMed Pharmaceuticals Inc, Key Employees 25
List of Figures
OncoMed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
OncoMed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
OncoMed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
OncoMed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
OncoMed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
OncoMed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
OncoMed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
OncoMed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
OncoMed Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10